ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial - The Lancet Oncology
ALT-803 + Nivolumab Found Safe, Effective in Metastatic NSCLC – Consult QD
Cancers | Free Full-Text | Heterodimeric IL-15 in Cancer Immunotherapy | HTML
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer | Journal for ImmunoTherapy of Cancer | Full Text
Frontiers | IL-15 in the Combination Immunotherapy of Cancer | Immunology
Frontiers | IL-15 in the Combination Immunotherapy of Cancer | Immunology
Frontiers | Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink | Immunology
Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model | Journal of Translational Medicine | Full Text
Cancers | Free Full-Text | Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions | HTML
MP15-12 PHASE IB TRIAL OF ALT-803, AN IL-15 SUPERAGONIST, PLUS BACILLUS CALMETTE GUERIN (BCG) FOR THE TREATMENT OF BCG-NAÏVE PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC). | Journal of Urology
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT- 803 to treat relapse after transplantation - ScienceDirect
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses* - Journal of Biological Chemistry
ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment | Journal of Virology
![PDF] Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/592693363cccb81f2d13bd956e5962fcc5426dd7/3-Figure1-1.png "PDF] Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models | Semantic Scholar")
PDF] Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models | Semantic Scholar
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT- 803 to treat relapse after transplantation - ScienceDirect
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial | Nature Medicine
The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas | Journal for ImmunoTherapy of Cancer
ALT-803 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
ASCO GU 2021: Phase II/III Clinical Results of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive NMIBC Carcinoma In Situ Patients
PK of ALT-803 in cynomolgus monkeys. Serum concentrations of ALT-803... | Download Scientific Diagram
aLT-803 promotes innate-like CD8 + T-cell effector activity and... | Download Scientific Diagram
New immunotherapy for lung cancer shows promise of success | MUSC Research
ALT-803 enhances NEO-201-mediated ADCC against human carcinoma cell... | Download Scientific Diagram
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial - The Lancet Oncology
